2-methyl-4-methoxybenzo[b]thiophene | 52526-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 2-methyl-4-methoxybenzo[b]thiophene
• 英文别名: 4-Methoxy-2-methylbenzo[b]thiophene；4-methoxy-2-methyl-1-benzothiophene
• CAS: 52526-32-6
• 化学式: C₁₀H₁₀OS
• 分子量: 178.255
• InChiKey: MRJRPLSIILCKMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯并[B]噻吩-4-醇 在 四甲基乙二胺 、 叔丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 31.25h， 生成 2-methyl-4-methoxybenzo[b]thiophene
  参考文献：
  名称：

  Studies in sulfur heterocycles. Part 14.1 Application of heteroatom directed ortho-metallation in functionalisation of benzo[b]thiophene derivatives

  摘要：

  对 2-叔丁基二甲基硅基-4-甲氧基苯并[b]噻吩和 2-叔丁基二甲基硅基-4-氨基甲酰氧基苯并[b]噻吩进行异位原子定向正金属化，然后用亲电体进行淬火。对 4-氨基甲酰氧基苯并[b]噻吩进行了阴离子正-弗里斯重排。重排产物被用作合成新型线性融合噻吩异色烯的起始原料。

  DOI：

  10.1039/a803427c

文献信息

• NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：EP4001279A1

  公开（公告）日：2022-05-25

  The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

  本发明公开了式（Ia）化合物及其药学上可接受的盐类： 其可抑制冠状病毒的复制活性。本发明进一步涉及包含式（Ia）化合物或其药学上可接受的盐的药物组合物，以及治疗或预防有需要的受试者冠状病毒感染的方法，包括向受试者施用治疗有效量的式（Ia）化合物或其药学上可接受的盐。
• [EN] NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS<br/>[FR] NOUVEAUX AGENTS ANTIVIRAUX DÉRIVÉS DE SPIROPYRROLIDINE
  申请人：[en]ENANTA PHARMACEUTICALS, INC.

  公开号：WO2022109363A1

  公开（公告）日：2022-05-27

  The present invention discloses compounds of Formula (la), and pharmaceutically acceptable salts, thereof: Formula (Ia) which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (la) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (la) or a pharmaceutically acceptable salt thereof.
• Studies in sulfur heterocycles. Part 14.1 Application of heteroatom directed ortho-metallation in functionalisation of benzo[b]thiophene derivatives
  作者：Sasanka Sekhar Mandal、Subhendu Sekhar Samanta、Chaitali Deb、Asish De

  DOI：10.1039/a803427c

  日期：——

  Heteroatom directed ortho-metallation of 2-tert-butyldimethylsilyl-4-methoxybenzo[b]thiophene and 2-tert-butyldimethylsilyl-4-carbamoyloxybenzo[b]thiophene has been followed by quenching with electrophiles. Anionic ortho-Fries rearrangement has been carried out on 4-carbamoyloxybenzo[b]thiophene. The rearranged product has been used as the starting material in the synthesis of a novel linearly fused thienoisochromene.

  对 2-叔丁基二甲基硅基-4-甲氧基苯并[b]噻吩和 2-叔丁基二甲基硅基-4-氨基甲酰氧基苯并[b]噻吩进行异位原子定向正金属化，然后用亲电体进行淬火。对 4-氨基甲酰氧基苯并[b]噻吩进行了阴离子正-弗里斯重排。重排产物被用作合成新型线性融合噻吩异色烯的起始原料。